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Abstract
PURPOSE: Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such
as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC)
patients but have also increased treatment costs considerably. Recent evidence associates
KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the
cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab
treatment of chemorefractory mCRC patients. EXPERIMENTAL DESIGN: A life-long Markov
simulation model was used to estimate direct medical costs (€) and clinical effectiveness
(quality adjusted life years, QALYs) of the following strategies: KRAS testing, KRAS testing
with subsequent BRAF testing of KRAS-wildtypes (KRAS/BRAF), cetuximab treatment
without testing. Comparison was against no cetuximab treatment (reference strategy). In the
testing strategies, cetuximab treatment was initiated if no mutations were detected. Best
supportive care was given to all patients. Survival times/utilities were derived from published
randomised clinical trials. Costs were assessed from the perspective of the Swiss health
system.RESULTS: Average remaining life-time costs ranged from €3'983 (no cetuximab) to
€38'662 (no testing). Cetuximab treatment guided by KRAS/BRAF achieved gains of 0.491
QALYs compared to the reference strategy. The KRAS testing strategy achieved an additional
gain of 0.002 QALYs compared to KRAS/BRAF. KRAS/BRAF testing was the most
cost-effective approach when compared to the reference strategy (incremental
cost-effectiveness ratio: €62'653/QALY). CONCLUSION: New predictive tests for KRAS and
BRAF-status are currently being introduced in pathology. Despite substantial costs of
predictive testing, it is economically favourable to identify patients with KRAS and BRAF
wildtype status.
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STATEMENT OF TRANSLATIONAL RELEVANCE.  30 
Markers with a high predictive value, such as KRAS and BRAF gene-mutations, can 31 
help identifying patients who are likely or unlikely to benefit from anti-EGFR drugs 32 
such as cetuximab. Currently, no data is available on the health economic 33 
implications of testing for KRAS and/or BRAF gene-mutations prior to cetuximab 34 
treatment of metastatic colorectal cancer patients. Using state-of-the-art health 35 
economic methodology, this study is dealing with the current lack of economic data 36 
on this topic which is of highest relevance for oncologists, pathologists, and health 37 
policy makers. The model can also be used for comparable decision problems arising 38 
with other predictive tests in pathology.  39 
 40 
41 
 American Association for Cancer Research Copyright © 2011 
 on September 14, 2011clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 1, 2011; DOI:10.1158/1078-0432.CCR-10-2267
 3 
 
Abstract  42 
Purpose – monoclonal antibodies against the epidermal growth factor receptor 43 
(EGFR), such as cetuximab, have led to significant clinical benefits for metastatic 44 
colorectal cancer (mCRC) patients but have also increased treatment costs 45 
considerably. Recent evidence associates KRAS and BRAF mutations with 46 
resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive 47 
testing for KRAS and BRAF mutations, prior to cetuximab treatment of 48 
chemorefractory mCRC patients.  49 
Experimental Design – a life-long Markov simulation model was used to estimate 50 
direct medical costs (€) and clinical effectiveness (quality adjusted life years, QALYs) 51 
of the following strategies: KRAS testing, KRAS testing with subsequent BRAF 52 
testing of KRAS-wildtypes (KRAS/BRAF), cetuximab treatment without testing. 53 
Comparison was against no cetuximab treatment (reference strategy). In the testing 54 
strategies, cetuximab treatment was initiated if no mutations were detected. Best 55 
supportive care was given to all patients. Survival times/utilities were derived from 56 
published randomised clinical trials. Costs were assessed from the perspective of the 57 
Swiss health system. 58 
Results – Average remaining life-time costs ranged from €3’983 (no cetuximab) to 59 
€38’662 (no testing). Cetuximab treatment guided by KRAS/BRAF achieved gains of 60 
0.491 QALYs compared to the reference strategy. The KRAS testing strategy 61 
achieved an additional gain of 0.002 QALYs compared to KRAS/BRAF. KRAS/BRAF 62 
testing was the most cost-effective approach when compared to the reference 63 
strategy (incremental cost-effectiveness ratio: €62’653/QALY).  64 
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Conclusion – new predictive tests for KRAS and BRAF-status are currently being 65 
introduced in pathology. Despite substantial costs of predictive testing, it is 66 
economically favourable to identify patients with KRAS and BRAF wildtype status.  67 
68 
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Introduction 69 
Despite substantial progress in surgery and chemotherapy treatments, patients with 70 
metastatic colorectal cancer (mCRC) generally have a poor prognosis. Monoclonal 71 
antibody therapy targeted against the epidermal growth factor receptor (EGFR), e.g. 72 
cetuximab (Erbitux®, Merck KGaA, Germany) has led to significant clinical benefits in 73 
mCRC patients1. Overexpression and activation of EGFR and transduction of 74 
activation signal play an important role in tumor progression2, 3. Recent evidence 75 
suggests that genetic alteration of downstream regulator proteins like KRAS and 76 
BRAF are associated with lack of response to antibody therapy4-10. Prevalence of the 77 
KRAS proto-oncogen in mCRC is 30-45%6, 11-14, whereas about 10% of wild-type 78 
KRAS tumours show BRAF-V600E (BRAF) mutation13, 15. Mutations in KRAS and 79 
BRAF occur in a mutual exclusive manner in CRC cells16.  80 
KRAS and BRAF gene status can be assessed by formalin-fixed, paraffin-embedded 81 
tissue. Several methods are available to detect oncogenetic mutations of KRAS and 82 
BRAF like, e.g., direct dideoxy-sequence analysis (sequencing method), 83 
pyrosequencing or allele-specific real-time PCR or others17-21. However, the cycle 84 
sequence method is the “gold standard” for KRAS analysis22. In Swiss laboratories, 85 
DNA sequencing after Sanger (dye terminator cycle sequencing) is generally used23. 86 
Given high sensitivity and perfect specificity of these assays, false negative or false 87 
positive results are scarce, but cannot be ruled out entirely.  88 
Recently, the American Society of Clinical Oncology issued a provisional clinical 89 
opinion on testing for KRAS mutation in mCRC patients, stating that KRAS mutation 90 
should be assessed in patients with mCRC who are candidates for EGFR antibody 91 
therapy24. In case of a KRAS mutation, antibody treatment should not be 92 
administered24. However, international guidelines for performing and assessing 93 
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KRAS mutations are still being developed25. Testing for BRAF mutation has just 94 
started in some laboratories. Recent clinical evidence supports BRAF mutation 95 
analysis, although the available testing procedures are fairly expensive.  96 
Predictive testing helps selecting the treatments patients will most benefit from. 97 
Additional costs of novel predictive tests like KRAS and BRAF have to be balanced 98 
against cost savings associated with avoiding treatment of patients who will 99 
predictably not respond to antibody treatment. Markov models have already been 100 
used in the metastatic breast cancer setting to measure the cost-effectiveness of 101 
different testing strategies26, 27. However, the economic consequences of testing for 102 
KRAS and/or BRAF mutations in mCRC patients have not yet been studied. The 103 
objective of this analysis is to assess the cost-effectiveness of testing for 104 
KRAS/BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC 105 
patients, from a Swiss health care system perspective.  106 
I. Methods 107 
Overview of mCRC disease model 108 
Based on a previously used modelling framework28, we constructed a Markov state-109 
transition model with an one-months cycle length to assess the economic 110 
consequences associated with each testing strategy. Effectiveness was assessed in 111 
terms of quality-adjusted life-years (QALYs). On this basis, incremental cost-112 
effectiveness ratios (ICERs) were calculated. The time horizon of the analysis was 113 
life-long.  114 
Costs were assessed from the perspective of the Swiss health care system. 115 
Accordingly, non-medical direct costs and indirect costs were not taken into account. 116 
Direct medical costs included drug costs, costs for predictive testing (where 117 
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applicable), diagnostic procedures and hospitalization. Costs and effects were 118 
discounted at an annual rate of 3%29. Costs are expressed in Euros (€). An exchange 119 
rate of €1.00 = CHF1.50 was used (February 2010).  120 
The Markov model was implemented in TreeAge Pro® 2009 (TreeAge Software Inc, 121 
Williamstown, MA, USA).  122 
Patient population studied 123 
The model followed a hypothetical cohort of chemorefractory, mCRC patients aged 124 
50 years (45% female, 55% male)30. It was assumed that 70% of patients were wild-125 
type KRAS and that 8% of this group (6% of the total) had a BRAF mutation status8, 126 
16, 31, 32. The eligibility criteria of our patient population were defined by the phase III 127 
National Cancer Institute of Canada Trial Group CO.17 (CO.17) study33. In brief, 128 
patients had advanced colorectal cancer (Eastern Cooperative Oncology Group 129 
performance status 0-2) with immunohistochemically detectable EGFR expression. 130 
They were chemorefractory and no other anticancer therapy was available33. The 131 
influence of all-cause mortality on the survival experience of the cohort was modeled 132 
using Swiss life tables34. 133 
Strategies compared 134 
Following testing strategies were assessed: KRAS alone and a sequential approach 135 
with BRAF testing of all KRAS wild-type patients. Patients with KRAS wild-type (in 136 
the KRAS alone strategy), or with KRAS wild-type/BRAF wild-type status, received 137 
cetuximab. Best supportive care (BSC) was administered to patients with KRAS 138 
mutation or BRAF mutation. Costs and effects of the no cetuximab treatment strategy 139 
served as reference values. Administering cetuximab to the entire patient population 140 
without prior predictive testing (no testing strategy) was added to estimate the overall 141 
benefit of predictive testing. 142 
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The occurrence of false positive and false negative test results may have severe 143 
consequences for the affected patients. Information on sensitivity and specificity of 144 
mutation analyses (sequencing method) were derived from published literature22. The 145 
probabilities of false positive and false negative test results were assumed to be the 146 
same for KRAS and BRAF, each taken by itself. Sensitivity and specificity of the 147 
KRAS and BRAF testing strategy were evaluated according to the “believe-the-148 
positive” approach, i.e. the combined result was positive if one test indicated a 149 
positive result (mutation). Both tests were regarded as conditionally independent 150 
(Table 1)35. 151 
Disease stages and clinical data sources 152 
The Markov model comprised three commonly exhaustive and mutually exclusive 153 
health states: stable/responsive disease, disease progression and death. All patients 154 
entered the model in the stable state and they could remain stable or progress. 155 
Patients with progressive disease could remain in this state or die (Figure 1).  156 
Clinical event rates for all patients under cetuximab or BSC were assessed from 157 
median times to progression and median times to death, as observed in the phase III 158 
randomized CO.17 trial32, 33 which compared BSC plus cetuximab with BSC. As an 159 
exception, event rates for patients with a BRAF mutation status under cetuximab 160 
treatment were extracted from a retrospective analysis of mCRC patients treated with 161 
cetuximab plus chemotherapy36. We assumed that patients with BRAF mutation 162 
receiving BSC would have the same event rates as patients with a KRAS mutation in 163 
the CO.17 BSC arm (Table 2). The treatment effect, namely transition probabilities 164 
for patients with KRAS wild-type and KRAS mutation, was hence modeled dependent 165 
on mutation status and treatment given4-6, 9, 32. Hazard rates (HRs) were assumed to 166 
be constant (HR=-ln(0.5)/median survival time) An exponential shape of the survival 167 
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curves was assumed. Transition probabilities were estimated from these rates using 168 
the standard formula, i.e. 1-e(rate*time). 169 
Utilities 170 
Preference-based measures of health-related quality of life were available from the 171 
CO.17 study. They were prospectively collected using the self-reported Health Utility 172 
Index Mark 3 (HUI3) questionnaire37, 38. Mean utility in the wild-type cetuximab group 173 
(stable disease state, responding to treatment) was 0.72 (CI 0.49-0.95) at baseline 174 
and increased over time (0.77; CI 0.55-0.99 at week 24). Mean utility in the BSC 175 
group was 0.71 (CI 0.47-0.95) at baseline and decreased over time (0.70 at week 24; 176 
CI 0.56-0.94)38. In our model, the latter values were applied to both wild-type and 177 
mutant patients in the stable disease state without cetuximab treatment and to 178 
mutant patients with cetuximab. For patients in the progression state, a value of 0.5 179 
(0.45-0.72) was assumed, as reported earlier in European studies 39, 40  180 
Medical resource use  181 
Best supportive care 182 
BSC was given to all patients. Given that patients were assumed to be 183 
chemorefractory, BSC therapy consisted mainly of palliation of symptoms and 184 
improvement of quality of life33, 41. Concomitant therapy (antibiotics, opiates, steroids, 185 
antithrombotics, antidiarrheals, antiemetics, blood formation products) and episodes 186 
of hospitalization were assumed to be the same for all patients, during a given period 187 
of time (e.g. month of follow-up)38. Quantities of medical interventions such as 188 
diagnostic and therapeutic interventions were assessed on the basis of published 189 
literature38. Length of average hospital stay for colorectal patients was based on data 190 
provided by the Swiss Federal Statistical Office (Appendix.1).  191 
 American Association for Cancer Research Copyright © 2011 
 on September 14, 2011clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 1, 2011; DOI:10.1158/1078-0432.CCR-10-2267
 10 
 
The model considered differences in medical resource use between the treatment 192 
groups (reference and cetuximab group) which arose from different survival times. 193 
Reference group  194 
All patients in the reference strategy (no cetuximab) received BSC only (as described 195 
above). Concomitant therapy, diagnostic ultrasound and palliative surgery including 196 
hospitalization were used in these patients. For the evaluation of disease status, all 197 
patients had a monthly medical consultation, chest radiologic imaging and cross-198 
sectional imaging every eight weeks, and a magnetic resonance imaging (MRI) at 199 
baseline (Appendix.1)33.  200 
Cetuximab group 201 
Patients with wild-type KRAS/BRAF status received BSC (as described above) plus 202 
cetuximab; in the no testing strategy all patients received BSC plus cetuximab. 203 
Cetuximab was given until disease progression or intolerable toxicity. For tumor 204 
evaluation, diagnostic tests were used as described above (Appendix.1)33. The 205 
cetuximab treatment group was assumed to have physician outpatient assessments 206 
every week due to the infusion schedule of the drug. The dosing regimen of 207 
cetuximab matched the treatment schedule described elsewhere32, 33. An intravenous 208 
loading dose of 400mg/m2 body surface area was followed by a weekly maintenance 209 
dose of 250mg/m2. Adjusting for the gender distribution in Swiss incident cases30, the 210 
model assumed a loading dose and a maintenance dose of 706mg and 441mg, 211 
respectively. Administration costs for drug infusion were taken into account.  212 
Unit costs 213 
Costs for laboratory tests, diagnostic interventions and drug administration time were 214 
estimated based on resource utilization, and were multiplied by unit costs drawn from 215 
the official Swiss tariff list (Tarmed)42. Drug costs were based on official Swiss 216 
 American Association for Cancer Research Copyright © 2011 
 on September 14, 2011clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 1, 2011; DOI:10.1158/1078-0432.CCR-10-2267
 11 
 
pharmacy prices (Appendix.1)43. Average hospital length of stay was obtained from 217 
Swiss hospital statistics44, 45. According to the Swiss Federal Office for Statistics, 218 
50% of hospital per diem costs were paid by Statutory Health Insurance, the rest is 219 
covered by cantonal authorities45, 46. Hence, the hospitalization costs were computed 220 
on this basis (case-based lump sum €1'127 plus daily rate of €152)44. Concomitant 221 
therapy was assumed to be the same for all patients, hence those costs were not 222 
included38.  223 
Sensitivity analysis 224 
Deterministic sensitivity analysis 225 
One-way sensitivity analyses assessed the robustness of the base-case results. 226 
Parameters subject to statistical uncertainty (utility values, sensitivity and specificity 227 
of mutation analyses) were varied within their 95% confidence intervals (CIs)47. The 228 
prevalence of KRAS and BRAF mutations was varied between 0.25-0.4017, 48 and 229 
0.05-0.2215, 49, respectively. Parameters representing overall survival and 230 
progression free survival were assessed by varying the underlying median times to 231 
event by ±25% or within their 95% CIs if available. Where 95% CIs were available, 232 
we checked whether such variation by ±25% would have been adequate. It was 233 
found to be a slightly conservative approach that rather overestimated the uncertainty 234 
in the survival time parameters. 235 
Variables not subject to statistical uncertainty were considered in scenario-analyses. 236 
Variables with direct impact on the ICER were varied by ±30%: costs of cetuximab, of 237 
mutation analyses, and of palliative care of metastatic disease. Medical resource use 238 
(diagnostic interventions) was varied in the BSC group only. Discount rates of 0% 239 
and 6% were additionally assessed  240 
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Probabilistic sensitivity analysis 241 
Probabilistic sensitivity analysis (PSA; second order Monte Carlo simulation) 242 
estimated overall parameter uncertainty around the base-case by using 10,000 sets 243 
of parameter values, which were randomly sampled from statistical distributions 244 
reflecting the ranges of variation used in deterministic sensitivity analysis50. Beta-245 
distributions were used for KRAS mutation/BRAF mutation prevalence, and test 246 
sensitivity and specificity and utility during stable disease and after progression. 247 
Gamma-distributions were used for median survival times and median time to 248 
progression. Unit costs were not subject to uncertainty and not included in the PSA42.  249 
II. Results 250 
Base-case analysis 251 
Cost 252 
In the base-case analysis, the addition of cetuximab to BSC increased costs 253 
considerably. As cetuximab use was restricted to patients who benefited most from 254 
therapy, the increase in costs in the testing strategies was distinctly lower than in the 255 
no-testing strategy. The costs of mutation analysis (€394 per analysis) were 256 
overcompensated by savings associated with the restriction of cetuximab 257 
administration to expected responders. Average lifetime per-patient costs were 258 
€34’771, €35’361 and €38’662 in the KRAS/BRAF, KRAS and no testing strategies, 259 
respectively. If KRAS/ BRAF testing was used, per-patient savings would be €590 260 
and €3’301 compared to KRAS testing and the no-testing strategy (Table 3).  261 
Effect 262 
Given imperfect sensitivity and specificity of the mutation analyses, different testing 263 
strategies led to different clinical outcomes (Table 1). Some patients had false 264 
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negative or false positive results and hence, received cetuximab or BSC treatment 265 
inappropriately, translating into QALY loss. Accordingly, the no testing strategy led to 266 
the highest QALY result (0.947 QALYs/patient). The KRAS/BRAF and KRAS testing 267 
strategies accrued 0.934 and 0.936 QALYs, respectively. The lowest result was 268 
observed in the reference strategy with no cetuximab use (0.443 QALYs) (Table 3).  269 
Incremental cost-effectiveness 270 
The least costly and least effective approach was the reference strategy (no 271 
cetuximab) (Table 3). Testing for KRAS and BRAF mutations led to average per-272 
patient costs of €30’788 and a quality-adjusted survival time of 0.491 QALYs, 273 
translating into an ICER of €62’653/QALY gained, compared to no cetuximab. 274 
Testing for KRAS only led to an ICER of €313’537/QALY versus KRAS and BRAF 275 
testing. The regimen with no predictive testing showed an even less favourable ICER 276 
(€314’588/QALY versus KRAS) (Figure 2).  277 
In Switzerland, about 4011 new colorectal cancer patients are registered annually 278 
(average 2003-2006)30. If 25% (1003) of these patients developed metastatic 279 
disease51, 52, KRAS and BRAF testing would lead to annual direct cost savings of 280 
€591’170 and a loss of 1.89 QALYs compared to KRAS. In comparison with no 281 
testing, KRAS and BRAF testing would save €3’902’673 and imply a loss of 12.41 282 
QALYs, per year. Compared to the no cetuximab strategy, the usage of KRAS and 283 
BRAF mutation analysis, with subsequent cetuximab administration where indicated, 284 
would require an annual net investment of about €30.9 million to acquire a gain of 285 
493 QALYs. 286 
Sensitivity analysis 287 
The results of the deterministic sensitivity analyses indicated that varying the overall 288 
survival of wild-type KRAS patients with BSC or the utility value for progressive 289 
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disease had the strongest impact on the ICER (Appendix 2a) and 2b)). The rank 290 
order of strategies was sustained in all situations assessed. The impact of the 291 
scenario analyses on ICER results was minor (Appendix.3). 292 
In PSA, KRAS and BRAF testing was the dominant strategy over a willingness to pay 293 
range of €10’000-€40’000 per QALY gained. Beyond €40’000/QALY, KRAS became 294 
the preferred strategy (Figure 3). Further PSA results are presented in Appendix.4.  295 
Discussion and Conclusion 296 
This present work is the first study addressing the cost-effectiveness of predictive 297 
KRAS and BRAF testing, prior to cetuximab administration to mCRC patients. 298 
Testing for KRAS and BRAF status with subsequent cetuximab treatment of patients 299 
with confirmed wild-type showed the most favourable ICER, of €62’653/QALY gained 300 
compared to no cetuximab use. Robustness of results was ascertained in a wide 301 
range of sensitivity analyses.  302 
According to the revised prescribing information, mCRC patients with KRAS 303 
mutations are not recommended to receive cetuximab, as they are unlikely to benefit 304 
from anti-EGFR drugs53. Given this, KRAS assessment is routine practice in Swiss 305 
pathology laboratories. Recently, testing for BRAF mutations has been introduced as 306 
a result of growing evidence of predictive and prognostic value in mCRC patients 307 
considered for antibody treatment8, 16, 54, 55. Our results add to the rationale for these 308 
approaches.  309 
Predictive tests need to have appropriate sensitivity and specificity. For KRAS and 310 
BRAF, sequencing analysis is frequently used, as was assumed in our model56. 311 
Direct sequencing analysis is characterised by its potential to detect all mutations, 312 
leading to very high specificity23. On the other hand, this method may feature a lack 313 
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in sensitivity compared to other techniques56. In consequence, some patients with 314 
KRAS or BRAS mutations may still receive anti-EGFR treatment.  315 
Further EGFR downstream regulators have been associated with lack of response to 316 
monoclonal antibodies in mCRC, e.g. loss in PTEN expression3 or PIK3CA 317 
mutation57. However, the evaluation of PTEN requires more standardization and is 318 
not yet ready for the clinical setting57, 58. Furthermore, the real predictive value of 319 
PIK3CA mutations is not firmly established36. Due to the complexity of the signalling 320 
pattern, it is likely that future predictive test assays will include several molecular 321 
biomarkers before antibody treatment. The appraisal of costs and effectiveness of 322 
new test assays is a pending task.  323 
Cost-effectiveness thresholds for clinical interventions vary between countries. 324 
Threshold values of $50’000-$100’000 (€38’500-€77’000) per QALY gained (USA) or 325 
£20’000-£30’000 (€23’000-€35’000) per QALY gained (UK) are regarded as realistic 326 
in the literature59. However, Braithwaite et al. revealed that current resource 327 
allocation preferences among the population of the USA are not consistent with these 328 
thresholds60. They estimated a social willingness to pay between $109’000/QALY 329 
(€86’500/QALY) and $297’000/QALY (€235’600/QALY) when considering the impact 330 
of health care on quality as well as quantity of life. Also, it can be assumed that the 331 
UK thresholds (NICE; National Institute for Health and Clinical Excellence) are stricter 332 
than the limits usually accepted in Switzerland.  333 
Mittmann et al. conducted an economic evaluation of cetuximab therapy for mCRC 334 
patients38. In a sub-analysis, they assessed cetuximab versus BSC in KRAS wild-335 
type patients. The resulting ICER of €144’360 (CI: €100’737-€258’896) per QALY 336 
gained is unfavorable compared with our result. The authors found a QALY 337 
difference of 0.18, which is about half of our estimated QALY gain. A likely reason for 338 
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this apparent discrepancy is that Mittmann et al. restricted the time horizon of their 339 
analysis to the observation period of the CO.17 trial (18-19 months, during which 340 
77% and 82% patients in the cetuximab and BSC arms died, respectively)33, 38. In 341 
contrast, our model used a life-long time horizon, in line with good health economic 342 
practice for the assessment of interventions with life-long consequences or an impact 343 
on survival61. Taking into account the full survival experience of all patients inclusive 344 
of longer-term survivors, using appropriate modeling techniques, lead to a higher 345 
accumulation of QALYs gained and is likely to explain our more favorable ICER 346 
results. A further health economic analysis found an ICER of about €70'000/QALY for 347 
cetuximab in combination with chemotherapy41. This analysis did not differentiate 348 
between KRAS mutant and wild-type patients, although it was mentioned by the 349 
authors that factors specific to the patient population should be considered. 350 
Some limitations of our study are related to data availability. Starting with a clearly 351 
defined patient population, we tried to identify the most appropriate model inputs 352 
currently available from the literature. However, clinical evidence from biomarker-353 
based randomized trials is scarce in the colorectal cancer setting. Hence, clinical and 354 
utility data originated from few studies conducted outside Switzerland8, 32, 33, 38. It is 355 
our understanding that the clinical data sources used in the model are the most 356 
appropriate ones that are available from the published literature. Evidence on clinical 357 
effectiveness stems from a sub-group analysis of patients recruited to the prospective 358 
randomized clinical trial by Karapetis et al32 as well as from a retrospective analysis 359 
(De Roock)36. The event rates (median overall and progression free survival) for 360 
BRAF wild-type/mutation seen in the latter study are consistent with other, smaller 361 
studies8, 62. All of these studies enrolled chemorefractory advanced colorectal cancer 362 
patients that were treated with BSC or cetuximab plus BSC. Based on the baseline 363 
characteristics of these studies, the patient collectives can be assumed to be 364 
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comparable. Given the uncertainty present in the trial data, and potentially limited 365 
transferability to routine clinical practice populations, extensive sensitivity analyses 366 
have been carried out.  367 
Available quality of life and utility data allowed to differentiate on the basis of 368 
cetuximab treatment versus BSC, but not on the basis of mutation status. Given that 369 
both BRAF and KRAS mutation is associated with a similar lack of response to 370 
cetuximab, similar quality of life was assumed in non-responders as in BCS-treated 371 
patients. Furthermore, differences in QALY results originated mainly from differences 372 
in survival time due to mutation status and treatment given. This instance has been 373 
fully incorporated into our analysis. Utility values had to be drawn from non-Swiss 374 
sources although there might be some differences in clinical treatment schedules or 375 
perception of quality of life. In particular, the utility value for progressive disease had 376 
a substantial influence on the main ICER result, although it did not change the final 377 
conclusion. While being aware of this limitation, we included the foreign data as the 378 
best available source of clinical evidence. Information on clinical resource use was 379 
primarily clinical trial-based and deviations from routine practice patterns may have 380 
occured. However, varying the use of diagnostic procedures in the BSC group did not 381 
impact the main result.  382 
Of note, this economic analysis is focusing on patients with late stage, chemo-383 
refractory cancer. Latest evidence implies that cetuximab first-line treatment of 384 
mCRC leads to significant response in KRAS/BRAF wild-type patients63. However, 385 
BRAF mutation seemed to have no impact on response to the antibody, suggesting 386 
that BRAF mutation may not have the same predictive value in first-line and chemo-387 
refractory tumors.  388 
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In conclusion, testing for KRAS and BRAF mutations prior to cetuximab treatment of 389 
chemorefractory mCRC patients is clinically appropriate and economically favorable, 390 
despite high costs for predictive testing. 391 
Acknowledgment 392 
We thank Prof. Richard Herrmann, University Hospital Basel, Switzerland, and Dr. 393 
Sara De Dosso, Oncology Institute of Southern Switzerland, Switzerland for 394 
commenting on clinical issues and Prof. Leonhard Held, Biostatistics Unit, Institute for 395 
Social and Preventive Medicine, University of Zurich Switzerland, for commenting in 396 
methodological issues. 397 
 398 
 399 
Figure legend 400 
Figure 1. Overview of Markov Model 401 
Legend: CET, cetuximab; Ref, reference strategy 402 
Figure 2. Base case cost-effectiveness analysis 403 
Legend: CET, cetuximab; Ref, reference strategy; QALY, quality adjusted life 404 
year.  405 
Figure 3. Probabilistic sensitivity analysis (Acceptability frontier*) 406 
Legend: *The cost–effectiveness acceptability frontier shows the PSA-based 407 
probability of strategies being cost–effective. For different willingness to pay 408 
thresholds, different strategies are optimal. For each threshold, only the 409 
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probability for the optimal strategy is shown. The no-testing strategy is not 410 
displayed in the figure.  411 
Ref, reference strategy; prob, probability.  412 
 413 
414 
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Table 1. Strategies and characteristics of predictive tests  415 
Test strategy Test result Treatment Sensitivity (95%CI) Specificity (95%CI) Ref.
KRAS KRAS wt 
KRAS mt 
CET 
BSC 
0.955 (0.917-0.979) 0.997 (0.982-1.0) 22 
KRAS and BRAF** KRAS wt/ BRAF wt 
KRAS wt/ BRAF mt 
KRAS mt 
CET 
BSC 
BSC 
0.998 (0.993-0.9996) 
0.998 (0.993-0.9996) 
0.955 (0.917-0.979) 
0.994 (0.964-1.0) 
0.994 (0.964-1.0) 
0.997 (0.982-1.0) 
22, 35 
No test - All CET - - - 
No CET (no test)* - All BSC - - - 
*Reference strategy 416 
**BTP: Belief the positive. One positive test result is sufficient for an overall positive result. The overall result is negative if both 417 
tests are negative. 418 
BSC, best supportive care; CET, cetuximab; Mt, mutant; wt, wild-type.  419 
 420 
421 
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Table 2. Clinical input parameters: survival according to mutation status and treatment 422 
strategy  423 
Mutation status  Ref. Ref. 
 KRAS wt   wt mt  
BRAF wt mt  - -  
Median OS 
(months) 
CET 13.0 6.5 36 9.5 4.5 32 
BSC 4.8 4.6 32 4.8 4.6 32 
Median PFS 
(months) 
CET 7.0 2.0 36 3.7 1.8 32 
BSC 1.9 1.8 32 1.9 1.8 32 
BSC, best supportive care; CET, cetuximab; Mt, mutation; wt, wild-type; PFS, progression free survival; OS, overall survival.  424 
425 
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Table 3. Base-case cost-effectiveness analysis of different testing strategies  426 
Test strategy Lifetime cost per 
person 
Lifetime efficacy Incremental 
costs* 
Incremental 
efficacy* 
ICER 
Unit € QALY € QALY €/QALY 
Reference (No 
CET, no test) 
3'983 0.4430 - - - 
KRAS and BRAF 34’771 0.934 300788a 0.491a 62’653a 
KRAS  35’361 0.936 590b 0.002b 313’537b 
No test 38’662 0.947 3’301c 0.010c 314’588c 
*Relative to the strategy with the next lower cost 427 
aCompared to the reference strategy (no CET) 428 
bCompared to KRAS/BRAF 429 
cCompared to KRAS 430 
CET, cetuximab; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year.  431 
 432 
 433 
434 
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